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 Introduction 
 Th e Institute of Medicine (IOM) through its Clinical Research 
Roundtable series beginning in 2000 identifi ed translational 
research as crucial to improving the health of the nation. Th ese 
meetings were the fi rst to defi ne blocks to the translation of 
discovery to patients: Th e T1 block acknowledged the diffi  culties 
of moving a laboratory fi nding into patients. Th e T2 blockade 
referred to the diffi  culties of adopting new, approved drugs 
and devices into general medical practice. 1,2 Th e translational 
paradigm has since been subdivided into four steps (see 
 Figure 1 ): T1 research seeks to move a basic discovery into a 
candidate health application; T2 research assesses the value of 
T1 application for health practice leading to the development 
of evidence-based guidelines; T3 research attempts to move 
evidence-based guidelines into health practice through delivery, 
dissemination, and diff usion research; T4 research seeks to 
evaluate the “real-world” health outcomes of a T1 application 
in practice. 2,3 Translational research encompasses the eff ective 
movement of new knowledge and discoveries into new approaches 
for prevention, diagnosis, and treatment of disease. 1–3 
 Within the T1 blockage sits the translational gap known as the 
“valley of death.” 4,5 Th e valley of death refers to the lack of funding 
and support for research that moves basic science discoveries 
into diagnostics, devices, and treatments in humans (see 
Figure 2 ). Traditionally, the valley of death is ascribed to be the 
result of the National Institutes of Health and pharmaceutical 
companies not willing to fund research development that may 
not result in a drug or device that will be utilized in the clinic 
and conversely, the fact that researchers do not have access to 
the funding needed to carry out the preclinical and early clinical 
development to demonstrate potential effi  cacy in humans. 
 Funding, however, is not the only reason the valley of death 
exists. Bridging the translational gap is dependent on successfully 
managing an additional four risks: scientifi c, intellectual property 
(IP), market (commercialization), and regulatory. Scientifi c risk 
includes all of the proof of concept issues that arise as part of 
preclinical and clinical investigations, including target validation 
as well as eventual safety testing. IP includes novelty of concept, 
existing patents, and competitive technologies. Commercialization 
risk encompasses whether the product based on discovery will be 
a market leader or follower, the size of the market, time to market, 
and investment needed for successful launch. Regulatory needs 
require understanding the appropriate path and Food and Drug 
Administration (FDA) requirements necessary for approval. 
 Since 2005, the University of Michigan (UM) has partnered 
with the Wallace H. Coulter Foundation (CF) to not only fund 
research that spans the valley of death but also create a model that 
provide an infrastructure for programmatic support to overcome 
the scientifi c, IP, market, and regulatory risks. 
 University of Michigan-Coulter Foundation (UM-CF) Program 
 Th e overall goal of the Coulter Translational Research Partnership 
Program is to achieve excellence and sustainability in translational 
research in biomedical engineering in perpetuity. Th e CF funded 
similar programs at eight other academic institutions. Each 
institution was provided with an initial grant of $580,000 per 
year with the intent to fund each for 5 years. Starting in the second 
year of funding this was raised to $1 million per year. In years 
4 and 5, the program was further supplemented with $100,000 per 
year by the Michigan Institute for Clinical and Health Research 
(MICHR) that houses the Clinical and Translational Science 
Award (CTSA) of the UM. 
 Th e goal of the UM-CF program is to support collaborative 
research that addresses unmet clinical needs and leads to 
improvements in health care and to commercial products. 
The program supports collaborative translational research 
projects that involve co-investigators from the Department 
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of Biomedical Engineering (BME) and a clinical department 
to create translational teams. Examples of desirable outcomes 
include inventions, patents, improved diagnosis and treatment 
of disease, commercial partnerships, start-up companies, and 
follow-on funding targeted toward these same outcomes. 
 Project selection involves more than just funding the best peer-
reviewed translational science. To be chosen for the program, each 
potential project is assessed for market potential, IP, regulatory 
strategy, reimbursement, and product development activities. 
Th e program also relies heavily upon the Coulter Oversight 
Committee (OC) at Michigan for project selection, monitoring, 
and mentoring. 
 Process for choosing projects: A Call for Proposals is issued in 
the fall and faculty with both full-time and part-time appointments 
in the BME Department are encouraged to submit a proposal. 
Proposals are “triaged” by the OC to assess the translational nature 
of each project. Finalists are invited to make presentations to the 
OC at a meeting in early spring where funding is determined for 
the year. Project cycles run from April 1 through March 31. 
 Projects are selected, reviewed, and assessed by the OC. Th e 
mission of the OC is to ensure the quality of translational projects 
and the sustainability of the Translational Partnership Program. 
Th e OC consists of Th e Chair of the BME (Committee Chair), 
the Senior Associate Dean for Research of the Medical School, a 
senior-level research dean from the College of Engineering, one 
representative from the local business community experienced 
with entrepreneurial activity in biomedical products, one 
representative from the venture capital community experienced 
in early-stage biomedical investing, representatives from the UM’s 
Offi  ce of Technology Transfer, one clinical physician reviewer 
qualifi ed to judge the applications based upon their clinical 
relevance, one regulatory aff airs specialist as well as scientifi c/
technical reviewers as required to provide needed expertise. Th e 
Coulter Program Director (CPD) serves as an  ex offi  cio member 
of the OC. Th e OC performs the following specifi c roles: assist 
with team and proposal solicitation and development, review 
and select individual translational research projects that will be 
funded annually, assess quarterly reports for the projects and the 
program, evaluate the project portfolio, conduct an annual “post-
mortem” on killed projects, and provide mentoring to teams. Th is 
mentoring may involve individual meetings, identifi cation of 
specifi c technical, regulatory, marketing or strategic expertise, and 
introductions to possible sources of follow-on funding. Th e OC is 
also meant to provide regular feedback to the Program principal 
investigator (PI), co-principal investigator (Co-PI), and CPD 
about the program, program evaluation, and provide updates to 
the senior University administration as needed or requested . 
 An important part of the CPD and the OC is to provide 
mentoring to the teams around all areas of risk. Th is mentoring 
involves individual meetings, identifi cation of specifi c technical, 
regulatory, marketing or strategic expertise, and introductions 
to possible sources of follow-on funding. Projects are funded 
initially for one year. Projects that met goals are eligible for 
further funding. Projects that 
are not successful are stopped. 
Th e OC then conducts an annual 
“post-mortem” on killed projects 
to learn potential lessons to 
apply when identifying future 
projects. 
 Scientifi c risk 
 Is addressed through peer 
review. Applications are chosen 
for the quality of the underlying 
hypothesis and/or discovery, 
as well as the quality of the 
preliminary data. Th e research 
plan as well as the quality of 
the investigators is judged. 
In addition, the ability of the 
individual faculty to work as 
a team is assessed through the 
written application as well as at 
oral presentations. Th e research 
plan had to outline specifi c issues 
 Figure 1.  The translational continuum. The translational paradigm has been sub-
divided into four steps. T1 research is the traditional bench to bedside work that 
leads to approval of a drug, device, or diagnostic. T2 research assesses the value of 
the approved application in medical practice and establishes guidelines for use. T3 
research studies the movement of evidence-based guidelines into health practice 
through delivery, dissemination, and diffusion research. T4 research evaluates the 
“real-world” health outcomes of a T1 application in practice. 2 
 Figure 2.  Bridging the valley of death. The University of Michigan-Coulter Foundation Program addresses the major risks neces-
sary to translate a discovery to the clinic. These include scientifi c peer review, identifying funding, identifying potential markets, 
and managing intellectual property and regulatory risks. 
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that had to be overcome to bring the concept to market and had 
to be associated with specifi c milestones. Applications without 
the appropriate scientifi c rigor are not funded. 
 IP risk 
 Is assessed in several ways by the UM Offi  ce of Tech Transfer as 
well as the OC. Novelty of the discovery is assessed through patent 
searches. Infringing IP is identifi ed and assessment of freedom 
to operate is performed. If there is existing IP, expiration date of 
the patents is explored. Competitive technologies currently in the 
market or being brought to market are identifi ed. Research teams 
are asked to identify other research teams pursuing technology in 
the area. Applications without identifi able IP are not funded. 
 Market/commercialization risk 
 Is assessed by the research teams and the OC committee. Special 
emphasis is given to this area by ad hoc clinical experts as well as 
the members of the OC from the business community and the 
venture capital community. First and foremost, the discovery 
research has to be framed to deliver a commercial product with 
a defi ned market. Th e deliverable product is preferred to be a 
market leader or is thought to have the potential to displace an 
existing product. An estimate of the earliest likely timeframe that 
a product, whether it is a drug, device, or diagnostic, could make 
it to market is made. A critical question is whether a market will 
still exist in the time frame of development. 
 Regulatory risk 
 Is determined by the UM regulatory expert. Th e likely regulatory 
path (e.g., 510(k), Pre-market Approval Application (PMA), none) 
is identifi ed . Examples of recent similar products and their path 
to approval are sought. Types of clinical trials are identifi ed for 
these products. FDA guidance documents that cover the potential 
product are identifi ed and subsequent discussions with the FDA 
are facilitated. 
 Funding risk 
 Is determined. A plan for funding aft er the Coulter award 
expired is required for each successful project. Funding plans 
include National Institutes of Health (NIH)-R01 and other 
federal grants, Small Business Innovation Research (SBIR)/
Small Business Technology Transfer Research Program (STTR), 
Venture Capital, licenses, and philanthropy. A preliminary 
assessment of the typical necessary capital for development of 
a product is made. Applications without a follow-on funding 
plan are not funded . 
 Having completed fi ve rounds of applications, 19 projects 
have been funded to date. Th e result of these risk assessments were 
that in 2006, 4 of 6 applications were selected for funding, in 2007, 
6 of 14 applications were selected for funding, in 2008, 6 of 13 
applications were selected for funding, in 2009, 7 of 18 applications 
were selected for funding, and in 2010, 6 of 16 applications were 
selected for funding. Total Coulter funding for projects has been 
$3,174,928. Total nonproject related research grants generated 
has been $7 million. Th is has included both SBIR as well as R01 
grant funding. Th e amount of funding received for the purpose 
of advancing projects through the translational continuum 
(follow-on funding received) has been $21,700,000, the majority 
in venture capital funding for start-up companies. In fi nancial 
terms, this is a return on investment of nine to one in just 4 years. 
From an IP perspective, two disclosures, seven provisional patent 
applications, and 13 full patent applications have been generated. 
One example of a successful start-up is HistoSonics Inc., a new 
medical device company that is developing a noninvasive image 
guided and robotic tissue ablation technology. Histotripsy was 
developed by UM faculty as a platform that will potentially replace 
traditional surgical and minimally invasive methods to reduce 
patient trauma and health care costs. Th e fi rst clinical application 
will be treatment of benign prostatic hyperplasia, a prevalent 
condition in older men.  A second start-up company based on 
discoveries of UM faculty is Life Magnetics, Inc. Life Magnetics 
is developing an  in vitro diagnostic device and cartridge for 
rapidly determining the antimicrobial susceptibility of bacterial 
infections utilizing an instrument that can perform these tests in 
a time-scale of hours rather than days. 
 Bridging the valley of death requires more than simple 
funding. Th e UM-CF Partnership Program provides a model 
of institutional support that provides investigators a framework 
to successfully bridge the gap between the bench and the 
bedside. 
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